|

Effect of MTX Discontinuation on Shingrix Response in RA

RECRUITINGN/ASponsored by Konkuk University Medical Center
Actively Recruiting
PhaseN/A
SponsorKonkuk University Medical Center
Started2024-08-22
Est. completion2025-12-31
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06574594

Summary

The goal of this clinical trial is to learn if methotrexate discontinuation affect on immunogeneity of shingrix in RA patients. The main questions it aims to answer are: Discontinuation of methotrexate after shingrix immunization increase efficacy of the vaccine in patients with RA ? Researchers will compare humoral and cell-mediated immunity against herpes zoster in RA patients who are vaccinated by shingrix, and compare these immunity between RA patients with MTX discontinuation and MTX continuation groups. Participants will: Vaccinated with shingrix twice. MTX continuation group will keep taking MTX after shingrix vaccination, whereas MTX discontinuation group will stop MTX for 2 weeks after shingrix vaccination. Visit the clinic at baseline (first shingrix vaccination), 2 months later for 2nd shingrix vaccination, then 3 \& 6 months later from baseline to achieve blood sample.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* fulfill 2010 ACR/EULAR classification criteria for rheumatoid arthritis
* age over 19 years
* methotrexate user
* agree for vaccination with shingrix

Exclusion Criteria:

* have other form of inflammatory arthritis or autoimmune-mediated disease
* malignancy, current infection, pregnancy

Conditions2

ArthritisRheumatoid Arthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.